These antibodies demonstrated selective binding to AD-derived tau aggregates and no immunoreactivity to aggregates in CBD, PSP, and PiD, providing an additional support to the concept of disease-specific tau conformations [35]. The gene discussed is MAPT; the disease is Alzheimer disease.